Positron emission tomography measurement of tumor metabolism and growth: Its expanding role in oncology

Molecular Imaging and Biology

Volumn 8, Issue 3, 2006, Pages 141-150

  Shields, Anthony F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FDG PET; Metabolism; PET; Tumor

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3' FLUOROTHYMIDINE; ALGESTONE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CARBON 11; CETUXIMAB; CLEVUDINE; COPPER 64; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FETOPROTEIN; FIACITABINE; FLOXURIDINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; IMATINIB; KI 67 ANTIGEN; METHIONINE; ONYX 015; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN; THYMIDINE DERIVATIVE; THYMINE; TRACER; TRASTUZUMAB; TUMOR MARKER; UNINDEXED DRUG; WATER O 15;

AGE; ANATOMICAL VARIATION; ANTINEOPLASTIC ACTIVITY; BIOPSY TECHNIQUE; BLOOD ANALYSIS; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA SYNTHESIS; DRUG COST; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG UPTAKE; EARLY CANCER; EARLY DIAGNOSIS; FAMILIAL CANCER; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL STROMAL TUMOR; GENDER; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; IMMUNOHISTOLOGY; LIVER METASTASIS; METASTASIS POTENTIAL; PHYSICAL PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TOXICITY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; VALIDATION PROCESS; WEIGHT REDUCTION;

CELL PROLIFERATION; HUMANS; MEDICAL ONCOLOGY; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 33746920876     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-006-0039-2     Document Type: Review

References (64)

1. Henschke CI (2005) CT screening for lung cancer: Update 2005. Surg Oncol Clin N Am 14(4):761-776
2. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214 (Jan 1)
3. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
4. Valk PE, Bailey DL, Townsend DW, Maisey MN (2003) Positron emission tomography. London: Springer-Verlag
5. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A, 3rd, Galanis E, et al. (2003) Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 21(8):1498-1504
6. Toloza EM, Harpole L, McCrory DC (2003) Noninvasive staging of non-small cell lung cancer: A review of the current evidence. Chest 123(1Suppl.137S-146S)
7. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM (2004) Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240(3):438-47; discussion 447-450
8. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352(19):1977-1984
9. Choi JY, Jang HJ, Shim YM, Kim K, Lee KS, Lee KH, et al. (2004) 18F-FDG-PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: Prognostic implications. J Nucl Med 45(11):1843-1850
10. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. (2005) [18F]Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23(6):1136-1143
11. Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, et al. (2005) Prognostic significance of preoperative [18-F]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 241(2):286-294
12. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. (1999) Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17(10):3201-3206
13. Burge CN, Chang HR, Apple SK (2005) Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens? Breast
14. de Vos tot Nederveen Cappel WH, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, Griffioen G, et al. (2004) Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 109(3):468-471
15. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349(3):247-257
16. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139
17. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304(5676):1497-1500
18. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, et al. (1995) Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36(10):1766-1774
19. Linden HM, Stekhova S, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. (2004) HER2 expression and uptake of 18F-fluoroestradiol predict response of breast cancer to hormonal therapy. J Nucl Med 45:85-86P
20. Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, et al. (2003) Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30(4):607-611
21. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ (2003) Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: Relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys 55(5):1233-1238
22. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. (2005) Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46(2):253-260
23. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, et al. (1995) Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33(2):391-398
24. O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. (2005) Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N 4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61(5):1493-1502
25. Weber WA, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, et al. (2000) O-(2-[18F]Fluoroethyl)-l-tyrosineandl-[methyl-11C]methionine uptake in brain tumours: Initial results of a comparative study. Eur J Nucl Med 27(5):542-549
26. Pauleit D, Floeth F, Tellmann L, Hamacher K, Hautzel H, Muller HW, et al. (2004) Comparison of O-(2-18F-fluoroethyl)-l-tyrosine PET and 3-123I-iodo-alpha-methyl-l-tyrosine SPECT in brain tumors. J Nucl Med 45(3):374-381
27. 11C-acetate PET imaging of prostate cancer: Detection of recurrent disease at PSA relapse. J Nucl Med 44(4):549-555
28. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR (2002) Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168(1):273-280
29. 11C-choline PET and FDG-PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 31(8):1064-1072
30. Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N, et al. (2001) Characterization of acetate metabolism in tumor cells in relation to cell proliferation: Acetate metabolism in tumor cells. Nucl Med Biol 28(2):117-122
31. Christman D, Crawford EJ, Friedkin M, Wolf AP (1972) Detection of DNA synthesis in intact organisms with positron-emitting [methyl-11C]thymidine. Proc Nat Acad Sci USA 69(4)
32. Heidelberger C, Chaudhuri NK, Danneberg P, et al. (1957) Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179:663
33. Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, et al. (1999) 2-[C-11]Thymidine imaging of malignant brain tumors. Cancer Res 59(3):615-621
34. Martiat P, Ferrant A, Labar D, Cogneau M, Bol A, Michel C, et al. (1988) In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med 29:1633-1637
35. Shields A, Dohmen B, Mangner T, Lawhorn-Crews J, Machulla H-J, Muzik O, et al. (2000) Imaging of thoracic tumors with [18F]FLT. J Nucl Med 74P
36. Vander Borght T, Pauwels S, Lambotte L, Labar D, De Maeght S, Stroobandt G, et al. (1994) Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med 35(6):974-982
37. Gunn RN, Yap JT, Wells P, Osman S, Price P, Jones T, et al. (2000) A general method to correct PET data for tissue metabolites using a dual-scan approach. J Nucl Med 41(4):706-711
38. Mankoff DA, Shields AF, Graham MM, Link JM, Eary JF, Krohn KA (1998) Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: Compartmental model and mathematical analysis. J Nucl Med 39(6):1043-1055
39. Shields A, Briston D, Chandupatla S, Douglas K, Lawhorn-Crews J, Collins J, et al. (2005) A simplified analysis of [F-18]3′-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging 32:1269-1275
40. Langen P, Etzold G, Hintsche R, G. K (1969) 3′-Deoxy-3′-fluorothymidine, a new selective inhibitor of DNA-synthesis. Acta Biol Med Ger 23(6):759-766
41. Shields A, Grierson J, Stayanoff J, Lawhorn-Crews J, Obradovich J, Muzik O, et al. (1998) F-18 FLT can be used to image cell proliferation in vivo. J Nucl Med 39:228P
42. Buck AK, Schirrmeister H, Mattfeldt T, Reske SN (2004) Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 31(Suppl 1):S80-S87
43. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, et al. (2002) In vivo validati3′-deoxy-3′-[(18)F]fluorothymidine of 3′-deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: Correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8(11):3315-3323
44. van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH, et al. (2005) Comparison of 18F-FLT PET and 18F-FDG-PET in esophageal cancer. J Nucl Med 46(3):400-404
45. Gjedde A (1982) Calculation of cerebral glucose phosphorylation from brain uptake of glucose a1nalogs in vivo: A re-examination. Brain Res Rev 4:237-274
46. Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3:1-7
47. Shields AF (2003) Labeled pyrimdines in PET imaging. In: Valk PE, Bailey DL, Townsend DW, Maisey MN (eds) Positron emission tomography. London: Springer-Verlag, pp 715-724
48. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. (2003) Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44(9):1426-1431
49. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. (2005) Imaging proliferation in brain tumors with 18F-FLT PET: Comparison with 18F-FDG. J Nucl Med 46(6):945-952
50. Francis DL, Visvikis D, Costa DC, Arulampalam TH, Townsend C, Luthra SK, et al. (2003) Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 30(7):988-994
51. Conti P, Alauddin M, Fissekis J, Schmall B, Watanabe K (1995) Synthesis of 2′-fluoro-5-[11C]-methyl-1-beta-d-arabinofuranosyluracil ([11C]-FMAU): A potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol 22:783-789 (Aug. 6)
52. Mangner T, Klecker R, Anderson L, Shields A (2003) Synthesis of 2′-[18F]fluoro-2′-deoxy-β-d-arabinofuranosyl nucleotides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential pet agents for imaging cellular proliferation. Nucl Med Biol (30):215-224
53. Mangner TJ, Klecker R, Anderson L, Shields A (2001) Synthesis of 2′-[F-18]fluoro-2′-deoxy-β-d-arabinofuranosyl nucleosides. J Labelled Comp Radipharm 44:S912-S914
54. Sun H, Mangner TJ, Collins JM, Muzik O, Douglas K, Shields AF (2005) Imaging DNA synthesis in vivo with 18F-FMAU and PET. J Nucl Med 46(2):292-296
55. Sun H, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM, et al. (2005) Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging 32(1):15-22
56. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. (2003) 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39(14):2012-2020
57. Al-Sukhun S, Zalupski MM, Ben-Josef E, Vaitkevicius VK, Philip PA, Soulen R, et al. (2003) Chemoradiotherapy in the treatment of regional pancreatic carcinoma: A phase II study. Am J Clin Oncol 26(6):543-549
58. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43(8):1018-1027
59. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ (2001) Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19(11):2797-2803
60. MacManus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. (2003) Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 21(7):1285-1292
61. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. (2003) 3′-Deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63(13):3791-3798
62. Shields A, Lawhorn-Crews J, Briston D, Douglas K, Mangner T, Muzik O (2005) The reproducibility of FLT PET in patients with untreated non-small cell lung cancer. J Nucl Med 46:426
63. Minn H, Zasadny KR, Quint LE, Wahl RL (1995) Lung cancer: Reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-d-glucose uptake at PET. Radiology 196(1):167-173
64. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M (1999) Reproducibility of metabolic measurements in malignant tumors using FDG-PET. J Nucl Med 40(11):1771-1777